STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s Annual Meeting Steering Committee.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (eg, stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers’ bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivering content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
|To view disclosure information for all ENDO presenters, please view the full schedule. Within each session abstract and session description, speaker disclosure is presented.|
ANNUAL MEETING STEERING COMMITTEE
Gary D. Hammer, MD, PhD (Chair)
Consultant, Ionis, Orphagen, HRA Pharma, Embara; NCI Board of Scientific Counselors, Clinical Sci & Epid (BSC-CS&E), NIH; Founder, Owner, Consultant, Millendo (formerly Atterocor)
David Abbott, BSC, PhD
Consultant, Innocrin Pharmaceuticals
Caroline Apovian, MD
Advisory Board Member, Amylin, Nutrisystem, Sanofi Aventis, Scientific Intake, Gelesis, Novo Nordisk, Zafgen; Investigator, MYOS Corporation; Principal Investigator, Aspire Bariatrics, GI Dynamics; Advisory Board member, Principal Investigator, Orexigen; Consultant, EnteroMedics; Stockholder, Science Smart LLC
Guillaume Assié, MD, PhD
Speaker, Novartis Pharma, EDIMARK SAS
Felix Beuschlein, MD
Advisory Board member, Millendo (formerly Attecor)
Kerry Burnstein, PhD
Research Collaborator, Amgen, Inc.
Lisa Chow, MD
Unpaid Investigator, Eli Lilly
David D’Alessio, MD
Consultant, Lilly, Novo Nordisk, Janssen; Grant Recipient, Merck
Scott M. Dehm, PhD
Consultant, Gerson Lehrman Group, Inc., Guidepoint Global Advisors, L.E.K. Consulting, Astellas/Medivation
Peter Ebeling, AO, MBBS, MD
Grantee, Amgen, Novartis, GSK, Eli Lilly, Merck; Speaker, Amgen, Eli Lilly
Richard A. Feelders, MD, PhD
Research Grant recipient and speaker, Novartis
Lawrence S. Kirschner, MD, PhD
Consultant/Speaker Bureau member, Corcept; Consultant, Chiasma, Pfizer
John (Jack) Leahy, MD (Clinical Science Chair)
Advisory Board Member, Merck, sanofi, NovoNordisk, Jansson, Valeritas
Ana Luiza Maia, MS, MD, PhD
Speaker’s Bureau member and Consultant, Bayer HealthCare; Speaker’s Bureau member and Consultant, Principal Investigator Multicentric Studies, AstraZeneca; Reviewer, AIRC (Italian Funding Agency); Principal Investigator Multicentric Studies, GlaxoSmithKline Brasil (spouse)
Nicola Partridge, PhD
Consultant and Research Contract Recipient, Orthofix Inc.
Sally Radovick, MD
Consultant for GH Products, CVS Caremark
Agnes Schonbrunn, PhD
Scientific Advisory Board Member, Crinetics Pharmaceuticals (significant leadership position)
Stephanie Seminara, MD
Carolyn Smith, PhD (Basic Science Chair)
Member of Scientific Advisory Board, Pfizer,
Manuel Tena-Sempere, MD, PhD
Research Agreement, Ferring Ltd., Bionaturis Ltd.
Adrian Vella, MD, FRCP
Member of the Advisory Board, Sanofi-Aventis, Novartis; Investigator, VTV Therapeutics
Steven Waguespack, MD
Grant Recipient, Novartis
The following AMSC members reported no conflicts of interest:
The Endocrine Society staff associated with the development of this program reported no relevant financial relationships.
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.
The educational content in this self-assessment test relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information be disclosed to the learners. Uses of some pharmaceutical agents, medical devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the United States Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” uses be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before prescribing or recommending any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
The Endocrine Society is proud to partner with industry to advance excellence and promote scientific discovery, medical practice and human health.:
AbbVie Inc.; Alexion Pharmaceuticals, Inc.; Amarin Pharma Inc.; Amgen; Boehringer Ingelheim Pharmaceuticals, Inc. & Lilly USA, LLC; Dexcom, Inc.; Eisai Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company; Lilly USA, LLC, Ipsen Biopharmaceuticals, Inc.; The Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novo Nordisk Inc.; Radius Health, Inc.; Shire; and Ultragenyx Pharmaceutical Inc.